Clinical Trial · NCT04542863

The Molecular Imaging Research of F-18 Labeled DX600 PET Probe

Overview

Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for COVID-19 infection. DX600 is a polypeptide that can specific binding to ACE2 specifically with nanomolar affinity reported in literature. This study constrcuted a radio-tracer, DX600 Labeled by PET Radionuclide, to monitoring biodistribution ACE2 in human beings, evaluate the detection ability of radio-tracer in ACE2 over-expression tumors and dynamic changes of ACE2 expression under therapy.

Sponsor

Peking University Cancer Hospital & Institute

Phase

N/A

Contacts

Hua Zhu (CONTACT)

zhuhuabch@pku.edu.cn

010-88196495

ClinicalTrials.gov

NCT04542863

Drug / Compound

DX600

Isotope(s):

Target(s):

ACE-2

Ligand Class: Peptides

Eligibility

Inclusion

* Age \>3 years old; both sex;
ECoG 0 or 1;
use 18F-FDG PET/CT as baseline evaluation
Patients that would undergo biopsy or surgical operation with high ACE2 expression tumors such as colorectal cancer, renal cancer, pancreatic cancer, gastric cancer, liver cancer, lung cancer, brain cancer or suspected tumor.

Exclusion

* Significant hepatic or renal dysfunction;
Is Pregnant or ready to pregnant;
Suffering from claustrophobia or other mental diseases;
Refusal to join the clinical study;
Cannot lie on their back for half an hour;